The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Promising results from the AQUILA trial: daratumumab in high-risk smoldering myeloma
In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the AQUILA trial (NCT03301220), a Phase III randomized study comparing daratumumab monotherapy to observation in patients with high-risk smoldering myeloma. The trial results show that daratumumab monotherapy delays progression to active myeloma in these patients; however, the long-term follow-up results are eagerly awaited. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI generated)
AQUILA trial is being presented by Professor Dimopoulos. This is a phase 3 randomized study comparing daratumumab monotherapy versus observation in patients with high-risk smoldering myeloma. What has been clearly borne out in the trial results that will be presented at this ASH is that giving daratumumab as monotherapy delays progression in patients with high-risk smoldering myeloma to active myeloma...
AQUILA trial is being presented by Professor Dimopoulos. This is a phase 3 randomized study comparing daratumumab monotherapy versus observation in patients with high-risk smoldering myeloma. What has been clearly borne out in the trial results that will be presented at this ASH is that giving daratumumab as monotherapy delays progression in patients with high-risk smoldering myeloma to active myeloma. So the primary endpoint of this trial has been met but we are waiting to hear more about the side effects with daratumumab short-term and long-term in this particular trial, and also what’s of interest is a long-term follow-up which will come out later in subsequent conferences as to whether this means that there is an improvement in overall survival in these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
